BNP Paribas Financial Markets Purchases 65,027 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

BNP Paribas Financial Markets lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 6,009.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 66,109 shares of the biotechnology company's stock after purchasing an additional 65,027 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.22% of AnaptysBio worth $2,215,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ANAB. Frazier Life Sciences Management L.P. increased its position in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company's stock worth $54,270,000 after buying an additional 1,265,891 shares during the last quarter. FMR LLC boosted its stake in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company's stock worth $110,857,000 after acquiring an additional 438,557 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of AnaptysBio during the 3rd quarter valued at about $8,874,000. Victory Capital Management Inc. raised its stake in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company's stock valued at $7,948,000 after acquiring an additional 206,750 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company's stock worth $15,927,000 after purchasing an additional 168,813 shares during the last quarter.

Insider Activity

In related news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 8.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric J. Loumeau sold 8,720 shares of AnaptysBio stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the completion of the transaction, the insider now owns 7,020 shares of the company's stock, valued at $279,536.40. This trade represents a 55.40 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,440 shares of company stock worth $892,936. Corporate insiders own 33.70% of the company's stock.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB traded up $1.15 during trading on Friday, hitting $24.81. 660,214 shares of the stock were exchanged, compared to its average volume of 469,034. AnaptysBio, Inc. has a 1-year low of $15.78 and a 1-year high of $41.31. The company's fifty day simple moving average is $27.17 and its 200-day simple moving average is $29.63.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. Sell-side analysts predict that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Analyst Ratings Changes

ANAB has been the topic of a number of recent analyst reports. BTIG Research lowered shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. cut their target price on shares of AnaptysBio from $75.00 to $66.00 and set an "overweight" rating for the company in a research report on Tuesday, November 12th. Wedbush reaffirmed an "outperform" rating and issued a $42.00 price target on shares of AnaptysBio in a research report on Thursday, November 14th. HC Wainwright cut their price objective on AnaptysBio from $55.00 to $52.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Finally, Truist Financial increased their target price on AnaptysBio from $20.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday, August 15th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $54.64.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.